Julien Hadoux

3.7k total citations
113 papers, 1.8k citations indexed

About

Julien Hadoux is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Oncology. According to data from OpenAlex, Julien Hadoux has authored 113 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Endocrinology, Diabetes and Metabolism, 40 papers in Surgery and 37 papers in Oncology. Recurrent topics in Julien Hadoux's work include Thyroid Cancer Diagnosis and Treatment (46 papers), Neuroendocrine Tumor Research Advances (31 papers) and Lung Cancer Research Studies (27 papers). Julien Hadoux is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (46 papers), Neuroendocrine Tumor Research Advances (31 papers) and Lung Cancer Research Studies (27 papers). Julien Hadoux collaborates with scholars based in France, Italy and United States. Julien Hadoux's co-authors include Martin Schlumberger, Éric Baudin, Sophie Leboulleux, Jean‐Yves Scoazec, Abir Al Ghuzlan, Livia Lamartina, David Planchard, Caroline Caramella, Michel Ducreux and Dana M. Hartl and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer.

In The Last Decade

Julien Hadoux

105 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julien Hadoux France 20 874 794 666 547 458 113 1.8k
C. Chougnet France 17 794 0.9× 813 1.0× 689 1.0× 574 1.0× 479 1.0× 36 1.6k
Brian R. Untch United States 27 1.2k 1.4× 1.1k 1.4× 482 0.7× 669 1.2× 557 1.2× 55 2.2k
Maria A. Kouvaraki United States 14 842 1.0× 770 1.0× 637 1.0× 534 1.0× 504 1.1× 23 1.7k
Joakim Crona Sweden 21 446 0.5× 523 0.7× 778 1.2× 454 0.8× 946 2.1× 58 1.6k
Mirella Marino Italy 25 398 0.5× 727 0.9× 811 1.2× 1.7k 3.1× 420 0.9× 82 2.3k
A. Fornasiero Italy 17 700 0.8× 390 0.5× 238 0.4× 491 0.9× 303 0.7× 43 1.6k
A Boneu France 15 365 0.4× 387 0.5× 507 0.8× 205 0.4× 285 0.6× 30 1.2k
Daria Handkiewicz-Junak Poland 22 324 0.4× 284 0.4× 1.2k 1.7× 146 0.3× 539 1.2× 69 1.7k
Georg F. W. Scheumann Germany 11 311 0.4× 320 0.4× 884 1.3× 135 0.2× 602 1.3× 19 1.3k
Valeria Bottici Italy 27 746 0.9× 651 0.8× 2.7k 4.1× 113 0.2× 913 2.0× 58 3.2k

Countries citing papers authored by Julien Hadoux

Since Specialization
Citations

This map shows the geographic impact of Julien Hadoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Hadoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Hadoux more than expected).

Fields of papers citing papers by Julien Hadoux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Hadoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Hadoux. The network helps show where Julien Hadoux may publish in the future.

Co-authorship network of co-authors of Julien Hadoux

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Hadoux. A scholar is included among the top collaborators of Julien Hadoux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Hadoux. Julien Hadoux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Christine Do, Niki Christou, Julien Hadoux, & Désirèe Deandreis. (2025). Chapter 8: Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor. Annales d Endocrinologie. 86(1). 101697–101697.
2.
Cao, Christine Do, Yann Godbert, Stéphane Bardet, et al.. (2025). ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer. Annales d Endocrinologie. 86(4). 101735–101735.
3.
Porcelli, Tommaso, Sophie Moog, Julien Hadoux, et al.. (2025). Validation of the International Medullary Thyroid Carcinoma Grading System in Patients with Distant Metastases. Thyroid. 35(11). 1268–1276.
4.
5.
Brose, Marcia S., Bruce Robinson, Lori J. Wirth, et al.. (2024). Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC).. Journal of Clinical Oncology. 42(16_suppl). 11111–11111. 3 indexed citations
6.
Bellera, Carine, Jean‐Philippe Guégan, Julien Hadoux, et al.. (2024). 1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC). Annals of Oncology. 35. S1120–S1120. 1 indexed citations
7.
Hadoux, Julien, Pauline Afchain, Anne‐Ségolène Cottereau, et al.. (2024). Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network. Journal of Nuclear Medicine. 65(9). 1416–1422. 2 indexed citations
8.
9.
Baudin, Éric, Christine Do Cao, Éric Dansin, et al.. (2023). Surgery of primary lung carcinoid tumors at metastatic stage: A national study from the French Group of Endocrine Tumors ( GTE ) and ENDOCAN‐RENATEN network. Journal of Neuroendocrinology. 35(10). e13331–e13331. 1 indexed citations
10.
Wirth, Lori J., Vivek Subbiah, Francis P. Worden, et al.. (2023). 2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001. Annals of Oncology. 34. S1147–S1148. 3 indexed citations
11.
Hadoux, Julien, Abir Al Ghuzlan, Livia Lamartina, et al.. (2023). Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma. JCO Precision Oncology. 7(7). e2300053–e2300053. 12 indexed citations
12.
Ghuzlan, Abir Al, Dana M. Hartl, Sophie Moog, et al.. (2023). Impact of lymphovascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study. Endocrine. 83(1). 150–159. 5 indexed citations
13.
Boilève, Alice, Matthieu Faron, Arnaud Bayle, et al.. (2023). Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data. European Journal of Cancer. 186. 122–132. 7 indexed citations
14.
Oh, Do‐Youn, Alain P. Algazi, Jaume Capdevila, et al.. (2023). Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study. Cancer. 129(8). 1195–1204. 31 indexed citations
15.
16.
Faron, Matthieu, Livia Lamartina, S. Hescot, et al.. (2022). New endpoints in adrenocortical carcinoma studies: a mini review. Endocrine. 77(3). 419–424. 1 indexed citations
17.
Strosberg, Jonathan, Nobumasa Mizuno, Toshihiko Doi, et al.. (2020). Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clinical Cancer Research. 26(9). 2124–2130. 146 indexed citations
18.
Leboulleux, Sophie, Corinne Dupuy, Ludovic Lacroix, et al.. (2019). Redifferentiation of a BRAF K601E -Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment. Thyroid. 29(5). 735–742. 36 indexed citations
19.
20.
Teuff, Gwénaël Le, J. Guigay, Caroline Caramella, et al.. (2017). Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. European Journal of Cancer. 75. 259–267. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Chougnet Breakdown of academic impact, for papers by Brian R. Untch Breakdown of academic impact, for papers by Maria A. Kouvaraki Breakdown of academic impact, for papers by Joakim Crona Breakdown of academic impact, for papers by Mirella Marino Breakdown of academic impact, for papers by A. Fornasiero Breakdown of academic impact, for papers by A Boneu Breakdown of academic impact, for papers by Daria Handkiewicz-Junak Breakdown of academic impact, for papers by Georg F. W. Scheumann Breakdown of academic impact, for papers by Valeria Bottici
Rankless by CCL
2026